The efficacy of AN69 membrane for elimination of aminoglycoside.

The efficacy of AN69 membrane for elimination of aminoglycoside. - The efficacy of AN69 membrane for elimination of aminoglycoside.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004486

Enrollment

Registered

2010-11-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA infection

Interventions

Participants who administered 200mg of arbekacin are underwent hemodialysis using AN69 dialyzer, and their blood samples are assayed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) gave their or their relatives' written informed consent 2) age, 20 years or higher 3) patient who requires hemodialysis 4) MRSA infections, including suspicions

Exclusion criteria

Exclusion criteria: 1) patients taking angiotensin-converting enzyme inhibitor. 2) patients having history of hypersensitivity to arbekacin. 3) patients having family with hearing loss. 4) patients being participating other study, and having participated other study within three months. 5) other situation that doctor decides.

Design outcomes

Primary

Measure	Time frame
Change over time of blood concentration of arbekacin.	—

Secondary

Measure	Time frame
Calculation of pharmacokinetic parameters of arbekacin in hemodialysis patients using AN69 dialyzer.	—

Countries

Japan

Contacts

Public ContactHirata Sumio

Graduate school of Pharmaceutical Sciences, Kumamoto University Division of Clinical Pharmacology

096-371-4856

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026